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ABSTRACT The spread of acquired immune deﬁciency syndrome has increasingly become a great concern owing largely to
the failure of chemotherapies. The G48V is considered the key signature residue mutation of HIV-1 protease developing with
saquinavir therapy. Molecular dynamics simulations of the wild-type and the G48V HIV-1 protease complexed with saquinavir
were carried out to explore structure and interactions of the drug resistance. The molecular dynamics results combined with the
quantum-based and molecular mechanics Poisson-Boltzmann surface area calculations indicated a monoprotonation took
place on D25, one of the triad active site residues. The inhibitor binding of the triad residues and its interaction energy in the
mutant were similar to those in the wild-type. The overall structure of both complexes is almost identical. However, the steric
conﬂict of the substituted valine results in the conformational change of the P2 subsite and the disruption of hydrogen bonding
between the NH of the P2 subsite and the backbone CO of the mutated residue. The magnitude of interaction energy
changes was comparable to the experimental Ki data. The designing for a new drug should consider a reduction of steric
repulsion on P2 to enhance the activity toward this mutant strain.
INTRODUCTION
The spread of acquired immune deﬁciency syndrome (AIDS)
has constantly threatened the world because the disease leads
to a signiﬁcant loss of morbidity and mortality. Unfortu-
nately, chemotherapy for the disease has, in many cases,
failed to achieve complete viral suppression (Deeks, 2003).
This relies on the fact that the human immunodeﬁciency
virus (HIV) develops resistance to antiretroviral drugs by
genetic mutation. The development of novel drug targets and
HIV vaccine is promising but the results of those studies
remain far from the clinical stage. Understanding the mu-
tations that confer resistance to available drugs is thus an
urgent issue in HIV chemotherapy.
The HIV type-1 protease (HIV-1 PR) is an important
target for AIDS chemotherapy. This viral protein cleaves the
gag and pol nonfunctional polypeptide into functional
proteins essential for maturation of infectious HIV particles
(Debouck et al., 1987). The protein is a homodimer. Each
protein monomer consists of 99 amino acids (Meek et al.,
1989). From x-ray data (Fig. 1 B), the substrate/inhibitor
binding site is located at the dimer interface (Hong et al.,
1996, 2000; Jaskolski et al., 1991; Krohn et al., 1991; Swain
et al., 1990; Vondrasek and Wlodawer, 2002). As a member
of the aspartyl protease family, HIV-1 PR is composed of
the conserved sequences, so-called the binding triads:
D25-T26-G27 andD25#-T26#-G27#, of whichD25 andD25#
are known as the active site residues. These two ionizable
residues play a major role in the catalytic reaction.
Because of the therapeutically important enzyme, struc-
tural and functional studies have been carried out to gain
understanding of molecular mechanisms of the proteolytic
cleavage process (Hyland et al., 1991; Northrop, 2001;
Okimoto et al., 1999; Scott and Schiffer, 2000; Smith et al.,
1996). The size and the availability of high-resolution x-ray
structures of HIV-1 PR are amenable for molecular dynamics
(MD) technique to investigate the relationship of structure,
dynamics, and function of the enzyme (Collins et al., 1995;
Harte et al., 1992, 1990; Levy and Caﬂisch, 2003; Piana
et al., 2002; Scott and Schiffer, 2000) as well as to serve as
a test system for developing computational methodology
(Piana et al., 2004, 2001; Wang and Kollman, 2000; York
et al., 1993a). The MD approach has provided insightful
information on the enzyme-substrate interactions and
binding conformations, the protonation states of the active
site residues, the role of the ﬂexible ﬂap and the binding
waters, and drug resistance. Characterizations of structural
intermediates have been made useful for rational drug design
(Randolph and DeGoey, 2004; Roberts et al., 1990;
Rodriguez-Barrios and Gago, 2004).
Saquinavir (SQV, Fig. 1 A), a peptidomimetic protease
inhibitor, is clinically used to treat infected HIV patients. The
inhibitor containing a nonhydrolyzable hydroxyethylene
isostere was designed based on the transition state structure
in the enzyme-substrate complex. Combination of PR and re-
verse transcriptase inhibitors appears to be a highly effective
treatment against HIV (Boucher, 1996). The PR inhibitor
blocks the maturation step of the HIV life cycle, which is the
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crucial stage in the formation of new viral particles.
Nevertheless, the current cure with SQV has introduced
several resistant variants of HIV-1 PR, some of which can
dramatically reduce drug susceptibility (Vondrasek and
Wlodawer, 2002). G48V and L90M are considered as the
primary mutations commonly occurring in vivo or in vitro
(Eberle et al., 1995; Vaillancourt et al., 1999). These ‘‘signa-
ture’’ residue mutations can be associated with a dramatic
decrease in drug susceptibility. According to Ki values, the
G48V, L90M, and G48V/L90Mmutants decrease saquinavir
sensitivity by 13.5-, 3-, and 419-fold with respect to that of
the wild-type (wt) protease (Ermolieff et al., 1997).
Among common mutations associated with antiretroviral
drug resistance, G48V is a unique mutation characteristically
generated by SQV. In a view of substituted-type residue,
glycine was replaced by a bulkier side-chain residue. The
steric conﬂict of the mutant should involve in a destabiliza-
tion of the complex. Although several x-ray structures of the
HIV-1 PR provided valuable information on the inhibitor
binding, this is not the case for the primary resistance to
SQV. The crystal structure of the G48V complex is not yet
available. With the aid of the available x-ray data, the
molecular modeling techniques offer an opportunity to in-
vestigate the structural basis of the mutant enzyme (Prabu-
Jeyabalan et al., 2003; Swain et al., 1990).
The missing hydrogens in the structural data have led
to studies of the ionization state of the active site residues
D25/D25# (Smith et al., 1996; Wang et al., 1996; Wlodawer
and Vondrasek, 1998; Yamazaki et al., 1994). This subject is
important for drug design in a way to optimize the
interactions of the inhibitor with the enzyme. Different
protonation models were found depending upon the local
environment of the enzyme-inhibitor complex. The single
protonation at one of the two acidic residues has been most
commonly observed with the binding of the hydroxyl-
ethylene-based inhibitors (Baldwin et al., 1995; Chen and
Tropsha, 1995; Hyland et al., 1991; Smith et al., 1996; Wang
et al., 1996; Wlodawer and Vondrasek, 1998). From NMR
experiments, the neutral D25/D25# side chain (diprotona-
tion) was determined in the presence of inhibitor diol groups
(Yamazaki et al., 1994), whereas the dianionic form (unpro-
tonation) was observed in the free enzyme (Smith et al.,
1996; Wang and Kollman, 2000).
In this study, we employed a computational approach to
access information regarding molecular structure and dy-
namics of the G48V HIV-1 protease conferring to saquinavir
resistance. The MD simulations were carried out for the wt
and the G48V HIV-1 protease complexed with saquinavir in
explicit aqueous solution. The study of the protonation state
of the HIV-1 PR complexed with SQV has been carried
out before exploring the structure and dynamic data of the
signature resistance. The density functional theory (DFT),
ONIOM, and molecular mechanics Poisson-Boltzmann
surface area (MM/PBSA) methods have been performed to
identify the protonation model of the active site residues. The
MM/PBSA approach offers an efﬁcient computation for
calculating the binding free energy of biomolecules (Kollman
et al., 2000; Srinivasan et al., 1998; Wang and Kollman,
2000). The method has been extensively used to study
protein-ligand complexes. The quantum-based approach,
DFT and ONIOM, has been useful in providing accurate
energy information of the interested region. In particular, the
hybrid quantum mechanical/molecular mechanical (QM/
MM) method, ONIOM (our own N-layered integrated
molecular orbital and molecular mechanics), developed by
Morokuma, has been extended from small molecules to
biological applications (Friesner and Beachy, 1998; Moro-
kuma, 2002; Prabhakar et al., 2004; Torrent et al., 2002). Its
efﬁciency has been improved over the years. Simply, the
concept of the ONIOM approach is partitioning a large
molecular system into onion skin-like layers, and applying the
quantummechanics and molecular mechanics methods to the
deﬁned different parts (Morokuma, 2002). In the partitioned
system, the high-level quantum computations engage the
essential part of the central activity, whereas the lower-level
energy calculations take into account the contribution of the
remaining region. The comparison of MD results of the two
systems provides insightful details of how theG48Vmutant is
associated with saquinavir resistance. The study provided
fundamental principles on the molecular mechanism of
FIGURE 1 Schematic representation of saquinavir (A) and the wild-type
HIV-1 protease-saquinavir complex (B). According to a conventional clas-
siﬁcation of the protease subsites, the binding pockets are designated by the
inhibitor side chains P1, P2, P3, P1#, and P2#.
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inhibitor binding and resistance, which will be useful for
designing an anti-HIV inhibitor to combat AIDS.
METHODS
Before starting the MD simulations, the problem of the protonated state of
the active site residues was addressed, since such information cannot be
directly obtained from the x-ray data. Our approach consists of molecular
orbital energy calculations and solvent continuum free-energy calculations.
However, structural data of the complexes, particularly the structure of the
G48V-SQV, are not available, and the quantum-based computation for the
whole enzyme-inhibitor complex is not feasible. A strategy is developed.
First, MD simulations of the four protonation states for the wt and for the
G48V complexes were performed to obtain the protonation models, which
were subsequently subjected to calculate interaction and binding energies.
Details of the methodology are described as follows.
Initial structure
The x-ray structure of the wt HIV-1 PR complexed with Ro 31-8959,
saquinavir, (Protein Data Bank code 1HXB; 2.3 A˚ resolution) was used as
a starting model. All missing hydrogens of the protein were added using the
LEaP module in the AMBER 7 software package (Case et al., 2002). The
protonation state of the ionizable residues, theC- and theN-termini, except for
D25/25#, was assigned based on the predicted pKa values at pH 7. The pKas
of ionizable residues were calculated based on the Poisson-Boltzmann free-
energy calculations (see the pKa prediction). The results concluded that all
Lys, Arg, Glu, Asp, and the terminal groups are charged, whereas His was in
the neutral form. Protonation states of D25/25# were explicitly assigned into
four different ionizable states, including unprotonation, monoprotonation
(each site of D25 and D25#), and diprotonation (protonated at both aspartyl
residues). For the wt study, the simulated systems were labeled as wt-unpro,
wt-mono25, wt-mono25#, and wt-dipro, respectively.
The starting structure and force-ﬁeld parameters for the inhibitor were
obtained as follows. Hydrogens were added to the x-ray coordinates of SQV
(1HXB) by taking into account the hybridization of the covalent bonds.
Geometric optimization was subsequently performed at the Hartree-Fock
level with 6-31G** basis functions to adjust the bond-length involving
hydrogens. Then, the RESP ﬁtting procedure was employed to calculate
partial atomic charges of the inhibitor (Cornell et al., 1993). Force-ﬁeld
parameters of the inhibitor were assigned based on the atom types of the
Cornell et al. (1995) force-ﬁeld model. Gaussian 98 (Frisch et al., 2002) was
used to optimize themolecular structure, generate electrostatic potentials, and
calculate ab initio energies. Partial charge generation and assignment of the
force ﬁeld were performed using the Antechamber suite (Wang et al., 2001).
The preparation of the initial structure for the simulation of the G48V
mutant-SQV complex was similar to that of the wt complex. The com-
parative model of the mutant was constructed based on 1HXB because the
three-dimensional structure of the G48V-SQV complex is not available. It
should be noted that the x-ray structure of the double mutant, G48V/L90M-
SQV complex (1FB7) could be considered as an alternative template.
However, the x-ray coordinates of the second monomer of the double mutant
are not available. Thus, 1HXB is considered to be more appropriate as
a template. The simulated systems of the mutant complex consist of four
protonated states, which were deﬁned similar to those of the wt complex,
i.e., unprotonation (mt-unpro), monoprotonations (mt-mono25 and mt-
mono25#), and diprotonation (mt-dipro).
The next step was to incorporate the solvent and counterions into the
models previously prepared. The crystallographic waters were also included
in the simulations. Each model was solvated with the TIP3P waters
(Jorgensen et al., 1983) and neutralized by the counterions using the LEaP
module. The total number of the TIP3P waters in the periodic box for all
systems was in a range of 9100–9900 molecules.
Molecular dynamics simulations
Energy minimization and MD simulations were carried out using the
SANDER module of AMBER 7 (Case et al., 2002) with the Cornell force
ﬁeld (Cornell et al., 1995). The whole systems were subjected to energy
minimization within a range of 200–5000 steepest descent steps to avoid bad
contacts. It should be noted that position-restrained minimizations of some
particular regions were carried out for systems that clashed during mini-
mization because of incidental overlay of atoms. This procedure was re-
peated until there was no sign of bad contacts. The resulting protein structure
was compared with the before-minimized structure. Root mean-square
displacement (RMSD) for nonhydrogen atoms of the compared protein
structures showed that there were no RMSDs exceeding 0.1 A˚ in all systems.
The MD simulation was performed employing the periodic boundary
condition with the NPT ensemble. A Berendsen coupling time of 0.2 ps was
used to maintain the temperature and pressure of the systems (Berendsen
et al., 1984). The SHAKE algorithm (Ryckaert et al., 1977) was employed to
constrain all bonds involving hydrogens. The simulation time step of 2 fs
was used. All MD simulations were run with a 12 A˚ residue-based cutoff for
nonbonded interactions and the particle-mesh Ewald method was used for an
adequate treatment of long-range electrostatic interactions (York et al.,
1993a).
The simulation consists of thermalization, equilibration, and production
phases. Initially, the temperature of the system was gradually heated from
0 to 298 K during the ﬁrst 60 ps. Then, the systems were maintained at 298 K
until MD reached 400 ps of the simulation. Finally, the production phase
started from 400 ps to 1 ns of the simulation. The convergence of energies,
temperature, pressure, and global RMSD was used to verify the stability
of the systems. The MD trajectory was collected every 0.1 ps. The 600 ps
trajectory of the production phase was used to calculate the average structure.
All MD simulations were carried for 1 ns. Analysis of all MD trajectories i.e.,
RMSD, distances, torsion angles, etc. was carried out using the CARNAL
and Ptraj modules of AMBER 7. The geometry and stereochemistry of the
protein structure were validated using PROCHECK (Laskowski et al.,
1996). In summary, a total of eight systems for the MD simulations were
carried out.
Graphic visualization and presentation of protein structures were done
using RasMol, Swiss-Pdb Viewer (Guex and Peitsch, 1997), WebLab
Viewer (Accelrys, San Diego, CA), and MolScript (Kraulis, 1991).
The pKa prediction
An assumption used for assigning the protonation state of the ionizable
residues in the simulations was inspected by the prediction of the pKa
values. The method estimates the pKa shift by calculating the electrostatic
free energy of ionizable residues in the neutral and the charge states in
solution (Antosiewicz et al., 1994). The computations were done by solving
ﬁnite different Poisson-Boltzmann equations implemented in the University
of Houston Brownian Dynamics program (Davis et al., 1991). The protocols
describe as follows. Polar hydrogens were added to the x-ray model using
Insight II (Accelrys, San Diego, CA). For generating electrostatic potentials,
the model was then placed in a 653 653 65 dimension with a grid spacing
of 2.5 A˚. The focusing technique was additionally employed using ﬁner grid
spacing of 1.2, 0.75, and 0.25 A˚ for a cubic dimension of 15, 15, and 20,
respectively (Antosiewicz et al., 1994; Yang et al., 1993). Atomic radii and
charges available in the University of Houston Brownian Dynamics program
were originally derived from optimized potentials for liquid simulations and
CHARMm 22 parameter sets (Brooks et al., 1983; Jorgensen and Tirado-
Rives, 1988). The 1.4 A˚ probe radius with a resolution of 500 dots/atomic-
sphere was used. The calculations employed a solvent dielectric of 80 with
150 mM ionic strength, and a temperature of 298 K. A dielectric constant of
HIV-1 PR was examined by varying to 1, 4, and 20. We found that a protein
dielectric constant of 20 produced the best pKa prediction. A dielectric
constant of 1 and 4 yielded unusual pKa values due to an overestimation of
electrostatic potentials. This phenomenon is thoroughly discussed in an early
work (Antosiewicz et al., 1994).
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Protonation state of the HIV-1 PR
In an evaluation of the protonation state of D25/D25#, we employed three
different approaches: density functional theory, ONIOM, and MM/PBSA
methods. The DFT and ONIOM methods provide the interaction energy of
the complex, whereas the MM/PBSA calculates the binding free energy
(DGbinding). It should be noted that properties of the system should be
analyzed using the structure ensemble from the MD trajectory. However,
quantum chemical methods are too expensive to calculate such enormous
structural data. Alternatively, the statistically averaged structure obtained
from the 600 ps production phase of the MD trajectory was chosen as the
studied model.
The DFT method
In each protonation model, the cluster consists of the two triad residues,
D25-T26-G27 and D25#-T26#-G27#, and SQV (see Fig. 3 A). Atoms that are
not within the selected part were removed. To reduce possible terminal-
charge effect, both ends of the triad fragments were capped by CH3NH and
COCH3 groups. Geometric optimization was performed for the added
atoms. The energy for the model was computed using a single-point
calculation method with mixed basis sets. B3LYP/6-31 1 G** was deﬁned
explicitly on the carboxylate oxygens of D25 and D25#, and B3LYP/6-
31G** was assigned on all the remaining atoms. The quantum calculations
were carried out using the program Gaussian 98 (Frisch et al., 2002).
A general form of the interaction energy calculation of the enzyme-
inhibitor complex (DEEI) is the subtraction of the energy of the complex
(EEI) from that of the free enzyme (EE) and that of the free inhibitor (EI).
DEEI ¼ EEI  EE  EI: (1)
In this case, the model system contains a cluster of the two triads and
SQV. Thus, interaction energy of the complex (DEcluster) was estimated by
DEcluster ¼ Ecluster  EtriadA  EtriadB  ESQV; (2)
where Ecluster is the total energy of the cluster, and EtriadA, EtriadB, and ESQV
are the total energy of the isolated triads of chain A and B and the unbound
SQV, respectively.
The ONIOM method
To account for an effect of the protein environment, the QM/MM ONIOM
methodwas used. Here, the three-layers approach (ONIOM3)was performed
to reduce the boundary effect at the QM/MM junction but maintain
considerably accurate energy information. The method is described as
follows. The model of the HIV-1 PR-SQV complex was divided into three
regions:A,B, andC (see theAppendix). TheONIOM layers were represented
by inner (A), intermediate (A1 B), and real (A1 B1C). The inner layer, the
‘‘hot spot’’ region, consisting ofD25,D25#, andSQV,was treated at the high-
level of quantum chemical calculations using density functional theory
(B3LYP/6-31G**). The intermediate layer contains a total of 36 residues
including D25-D30, I47-F53, P80-I84, and L90. These residues are located
within a 5 A˚ distance from SQV. This intermediate layer was treated with the
semiempirical method using PM3. Lastly, the real layer includes the entire
enzyme. The molecular mechanic method using universal force ﬁeld (UFF)
was applied to this layer.All calculations based on theONIOMapproachwere
carried out using the program Gaussian 98 (Frisch et al., 2002).
Hence, the total energy obtained from the ONIOM3 calculations
(EONIOM3) herein can be deﬁned by (see the Appendix):
Eoniom3½ABC ¼ E½UFF;ABC1E½PM3;AB1E½B3LYP;A  E½UFF;AB
 E½PM3;A: ð3Þ
For the overlap regions, the subtraction energy terms are introduced to
substitute the low-level energy calculations with the high-level one.
Therefore, the total interaction energy (DEoniom3total [ABC]) between SQV and
the enzyme using the ONIOM3 method can be expressed as independent
energy components from each layer as follows:
DE
oniom3
total ½ABC ¼ DE½UFF;ABC1DE½PM3;AB1DE½B3LYP;A
 DE½UFF;AB  DE½PM3;A ð4Þ
DE
oniom3
total ½ABC ¼ DE½B3LYP;A1DDE½PM3;ABA
1DDE½UFF;ABCAB ð5Þ
DDE½PM3;ABA ¼ DE½PM3;AB  DE½PM3;A (6)
DDE½UFF;ABCAB ¼ DE½UFF;ABC  DE½UFF;AB; (7)
where DE½B3LYP;A is the interaction energy in the region A evaluated at the
B3LYP/6-31G(d,p) level. DDE½PM3;ABA is the interaction energy contrib-
uted from the region B evaluated at the PM3 level, and DDE½UFF;ABCABis
the interaction energy contributed from the region C evaluated at the UFF
molecular mechanics.
The MM/PBSA method
In general, the free energy of the inhibitor binding, DGbinding, is obtained
from the difference between the free energy of the receptor-ligand complex
(Gcpx), and the unbound receptor (Grec) and ligand (Glig) as follows:
DGbinding ¼ DGcpx ¼ Gcpx  ðGrec1GligÞ: (8)
The MM/PBSA approach calculates DGbinding on the basis of a
thermodynamic cycle. Therefore, Eq. 8 can be approximated as
DGbinding ¼ DEMM  TDS1DGsol; (9)
where DEMM is related to the enthalpic changes in the gas phase upon
binding and obtained from molecular mechanics van der Waals and
electrostatic energies, TDS involves the entropy effect, and DGsol is the free
energy of solvation. The DGsol is composed of the electrostatic and nonpolar
contributions (Srinivasan et al., 1998), and therefore can be expressed as
DGsol ¼ DGPB1DGSA; (10)
where DGPB is calculated using a continuum solvent model with Poisson-
Boltzmann solution (Gilson et al., 1987), and DGSA is estimated from the
solvent-accessible surface area (SASA) (Sitkoff et al., 1994).
The DGbinding was obtained using the MM/PBSA module in the program
AMBER 7, which interfaces the program DelPhi 4 (Rocchia et al., 2001). To
calculate electrostatic free energy of solvation, the grid resolution of 0.5 A˚
with the boundary conditions of Debye-Huckel potentials was employed.
Atomic charges were taken from the Cornell force ﬁeld (Cornell et al.,
1995). The water and protein dielectric was set to 80 and 4, respectively. The
SASA was calculated using a 1.4 A˚ probe radius. Atomic radii were taken
from the PARSE parameter set (Sitkoff et al., 1994). The nonpolar free
energy of solvation was obtained by 0.00542 3 SASA 1 0.92 kcal mol1
(Sitkoff et al., 1994).
In the study, the contribution of the entropy (TDS) was not included. An
estimation of the entropy effect from normal mode analysis requires the high
computation demands. The effect should be very small because all system
models are very similar. In addition, we considered the relative values of the
binding free energy.
RESULTS
Hydrogen bonding in the binding site
One of the most important HIV-1 PR-SQV interactions is
the formation of the hydrogen bond at the active site. This
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observation is estimated from the x-ray data by the close
proximity between the terminal side chain of the two aspartyl
residues and the hydroxylethylene isostere moiety (OH) of
the inhibitors. Due to the lack of hydrogen position in the
structure, the pattern of this typical hydrogen bond is in-
vestigated here. Therefore, it is necessary tomonitor the active
site structure of the MD results and determine the most
preferential interactions.
The MD snapshot of the dipro, mono25, mono25#, and
unpro systems for the wt and the G48V complexes is illus-
trated in Fig. 2, A–H. The D25/D25# side chains and the
OH of SQV of all protonated states, except for the
unprotonation, occupies the positions suitable for the forma-
tion of the hydrogen bond. The distal separation between the
active site residues and the hydroxylethylene isostere of
SQVmaintains similarity to the x-ray structure. The structure
of the wt-unpro and the mt-unpro provide the worst scenario
of the complex (Fig. 2, D and H). A majority of MD data
shows that the active site residues adopted to a conformation
completely different from the x-ray data. Hence, the wt-un-
pro and mt-unpro systems are not an appropriate state for the
formation of the HIV-1 PR-SQV complex.
In comparing the four protonated states, the binding
pattern of theOH of SQV to the D25/D25#was remarkably
different. Nevertheless, when comparing the wt with the
mutant structure of the same protonated state, the binding
pattern at the active site was similar. The results allow draw-
ing a simple scheme of the hydrogen bond pattern at the active
site, which is illustrated in Fig. 2, I–L.
Protonation state of the wild-type complex
From the pKa prediction, the D25/D25# in the free wt HIV-1
PR exhibited different protonation states depending on the
examined pHs of 4, 5, 6, and 7 because the assay of the HIV-1
PR is measured between pH 5 and 6, and in the basic solution
the enzyme precipitates (Wang et al., 1996). However, the
dianionic form was the most apparent state between pH 6 and
7. The protonation state at pH4 and 5 remains inconclusive. In
this study, these results were not fully understood. It is
possibly associated with the used parameters (atomic charges
and radii, dielectric constant, etc.) and the studiedmodel. This
awaits further investigation.
Table 1 shows the resulting energy calculated from DFT,
ONIOM, and MM/PBSA approaches. Here, the term ‘‘the
stabilization energy’’ is used for a simpler and more
straightforward deﬁnition. The negative sign of the stabiliza-
tion energy suggests that the protonation model of wt-dipro,
wt-mono25, and wt-mono25# systems are energetically
favorable. From the full quantumDFT treatment, theDEcluster
wt-mono25 compared to that of wt-dipro and wt-mono25#
was lower by 7.62 and 17.22 kcal mol1, respectively. The
lowest DEcpx from the ONIOM3 method also took place on
the protonation model of the wt-mono25. The energy
difference was 14.13 and 16.63 kcal mol1 more stable than
that of the wt-dipro and of the wt-mono25#, respectively.
From the MM/PBSA method, the stabilization energy of the
wt-mono25 systemwas slightly lower in energy than the other
two states. Apparently, all the three approaches showed that
the monoprotonation at D25 was the most energetically
favorable state.
FIGURE 2 MD snapshots showing
interactions in the binding pocket of the
wt and G48V for various protonation
states: diprotonation (dipro), mono-
protonation of D25 (mono25), mono-
protonation of D25# (mono25#), and
unprotonation (unpro). Saquinavir
(SQV) and the active site residues
D25 and D25# of the enzyme are shown
in stick mode. Chain A and B of the
enzyme are colored as blue and green.
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The stabilization energy shown in Table 1was decomposed
into individual energy components (Table 2) for analyzing
quantitatively essential interactions of the different pro-
tonation models. From the DFT method, an order of the
DEtriadA1SQV ranging from the lowest value was wt-dipro ,
wt-mono25 , wt-mono25#. The sum of DEtriadA1SQV and
DEtriadB1SQV was used to account for interactions of SQV
to the triad residues. Still the wt-diprowas the ﬁrst preferential
protonation model with the lowest energy of 34.19 kcal
mol1. Considering the sum of DEtriadA1SQV and
DEtriadB1SQV of wt-mono25, the energy difference was
7.51 kcal mol1 greater than that of wt-dipro. On the other
hand, its DEtriadA,B value accounting for the triad-triad
interactions has signiﬁcantly gained by 13.16 kcal mol1
over the wt-dipro system. These data suggested the interac-
tionsbetween the triadswere essential to the complex stability.
The ONIOM3 results showed the lowest DE[B3LYP,A] took
place on wt-mono25. It should be noted that DE[B3LYP,A]
has considered the interactions of SQV to D25 and to D25#,
and between D25/D25#. This is still the case when accounting
for interactions of the 5 A˚ neighboring residues to SQV
(DE[PM3,AB-A]). The DE[UFF,ABC-AB] of the three states are
almost equivalent. There was no signiﬁcant change of the
stabilization energy with an addition of DE[UFF,ABC-AB].
Thus, theeffect of theproteinenvironmentat the longdistance-
range interactions is negligible.
In the MM/PBSA method, there was no substantial dif-
ference of DEMM for all three systems, whereas the DGsol of
the wt-mono25 revealed the lowest values. This observation
suggests the solvation free-energy values dominate the contri-
bution of the stabilization energy. The molecular mechanics
energy term cannot discriminate the protonation model.
Interaction energy at the catalytic site: the
wild-type versus G48V
We have illustrated previously that the quantum-based
approach gave promising results to the characterization of
the complex model. Here, the approach has been further
exploited by calculating the enzyme-inhibitor interaction
energy of the G48V complex. The interaction energy of the
triads/SQV in the wt complex, DEcluster, previously obtained
using the DFT method (Table 1) was used for a comparison.
The results illustrated in Fig. 3 suggested that in the
G48V-SQV complex, the lowest DEcluster also took place
at the monoprotonated D25 model. The interaction energy
for both the wt and the G48V in the mono25 was ;8 and
17 kcalmol1 lower than those from the dipro and the
mono25#, respectively. At the same protonation state, the
DEcluster of the G48V was no essentially different from that
of the wt. This conclusion followed from the fact that the
thermal ﬂuctuation at room temperature of;0.6 kcalmol1,
equivalent to 1 kT, where T is 300 K and k is the Boltzmann
constant. Thus the interactions of the two triad residues and
SQV remain unchanged by the G48V mutation.
Those results discussed previously lead us to conclude that
the monoprotonation at D25 is the most energetically favor-
able state. Therefore, further comparison and discussion
for both the wt and the mutant complex were focused only
on the results of monoprotonation D25.
The energies and RMSD plots (Fig. 4) demonstrated
a well-behaved MD simulation for both the wt and G48V-
SQV systems. After 400 ps, the RMSD ﬂuctuates 1.27–1.78
A˚ for the wt and 1.29–1.80 A˚ for the mutant. The ﬂuctuation
is ,0.5 A˚ over the entire production phase. This structural
ﬂuctuation is not uncommon in the typical MD simulation of
protein, indicating the reliable equilibration of the system in
this study. In Table 3, the low RMSD values calculated from
100 snapshot structures taken from the production phase
suggested the structures in each set were similar to each
other. This allows useful information to be extracted from the
MD trajectories. Analysis of some statistic quantities such as
structure and dynamics was performed from the trajectories
of wt-mono25 and mt-mono25 systems.
TABLE 2 Decomposition of the stabilization energy (kcal mol21)
DFT ONIOM3 MM/PBSA
System DEtriadA1SQV DEtriadB1SQV DEtriadA,B DE[B3LYP,A] DE[PM3,AB-A] DE[UFF,ABC-AB] DE
MM DGsol
wt-dipro 23.81 10.38 27.64 11.45 36.66 16.11 109.42 17.81
wt-mono25 12.27 14.41 40.80 33.63 28.34 16.38 109.83 15.39
wt-mono25# 6.33 6.88 41.53 18.33 27.48 15.91 109.88 16.98
DEtriadA1SQV or DEtriadB1SQV account for interactions of the triad residues of chain A or B to SQV, and DEtriadA,B accounts for interactions between the triad
residues of chain A and those of chain B.
DE[B3LYP,A] accounts for interactions of D25, D25#, and SQV.
DE[PM3, AB-A] represents interactions of SQV and the 5 A˚ surrounding residues, excluding D25 and D25#, and DE[UFF,ABC-AB] represents interactions of SQV
and the remaining residues.
TABLE 1 The stabilization energy (kcal mol21)
DFT ONIOM3 MM/PBSA
System DEcluster DEcpx DGcpx
wt-dipro 59.32 64.22 91.62
wt-mono25 66.94 78.35 94.44
wt-mono25# 49.72 61.72 92.91
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Structural similarity between the wild-type and
the mutant
The global backbone RMSD of the x-ray versus the average
MD structure of the wt of 1.04 A˚ indicates that overall main-
chain structures of the complex in the crystal state and in
solution are similar. In addition, comparison of the two
average MD structures between the wt and the G48V mutant
resulted in a backbone RMSD of 0.70 A˚. This suggests that
the tertiary structure of the G48V mutant was insigniﬁcantly
different from the native enzyme.
Detailed analysis of RMSD per residue is illustrated in Fig.
5. One can see that most regions of the enzyme, except for the
ﬂexible loop of the ﬁrst subunit, exhibited a small difference
in backbone conformation of the wt enzyme with respect to
the mutant. Particularly, RMSDs of E21–D30 residues,
covering the triad sequence of the enzyme, were in a range
from 0.11 to 0.36 A˚. This indicates no essential structure
alteration of the main-chain hydroxyethylene isostere of SQV
and the surrounding residues. Thus, the contacts between the
hydroxyl of SQV and the active site residues were in-
dependent of the amino acid substitution at residue 48. This
result supported the evidence discussed previously that inter-
action energies of the two triad residues and saquinavir were
not signiﬁcantly changed by mutation of G48V.
Structural difference between the wild-type and
the mutant
In Fig. 5, the apparent difference between the wt and the
mutant HIV-1 PR-SQV complexes was observed around the
protein ﬂap (residues 46–55). In this region, overall RMSD
values of chain A were relatively greater than those of chain
B (Fig. 6). The structure of the ﬂap B of the G48V is similar
to that of the wt enzyme, whereas the b-hairpin structure of
the ﬂap A of the mutant does not superimpose well.
Surprisingly, the tip of ﬂap A of the G48V-SQV complex
shifted slightly toward the twofold axis of symmetry of HIV-1
PR. However, distance separations between the tips, residues
49–51 in the mutant, were not signiﬁcantly different from
that in the wt complex.
Flexibility and conformational changes of
SQV subsites
Flexibility and conformational changes of the inhibitor side
chains P1, P1#, P2, P2#, and P3 were investigated in terms of
torsion angle ﬂuctuations of xP1, xP1#, xP2, xP2#, and xP3,
respectively. From Fig. 7 A, an oscillation of all dihedral
angles throughout the simulations, which was no greater than
610, suggested that in the wt complex, all SQV side chains
undergo a narrow range of dynamic ﬂuctuation. In other
FIGURE 3 DEcpx between the triad residues and saquinavir of the wt and
the G48V complexes for the dipro, mono25, and mono25# systems.
FIGURE 4 Plots of the energies (A) and RMSDs (B) versus the simulation
time for the wt and G48V-SQV complex. The obtained RMSD was com-
puted using the structure at t ¼ 0 as a reference.
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words, the inhibitor side chains were inﬂexible and retained
their starting conformation during the course of the MD
trajectory. In the case of the G48V mutant, all torsion angles
except for xP2 adopted the values similar to that of the wt
(Fig. 7 B). This indicated that the conformations of these
subsites are unchanged. However, a remarkable shift in xP2
implied a rotation of the P2 subsite starting from ;70 to
its equilibrium value ;90. This suggested a substantial
rotation of the P2 of SQV in the G48V (Fig. 8). In addition,
the 640 ﬂuctuation of xP2 in the mutant larger than that
of the wt indicated that the P2 side chain looses its rigidity.
The rearrangement of the P2 was related to the event of the
ﬂap motion as describe previously. Moreover, it involves
a decrease of the strength of the hydrogen bond between
the mutated residue and the P2 subsite (described in the next
topic). The overall change in terms of torsion angles is
supposed to explain a decrease of saquinavir sensitivity.
Decrease of hydrogen bond strength
The MD results show that the conformational difference in
SQV subsites between the wt and the G48V complexes was
located at the P2 side chain. Among residues surrounding the
P2 subsite, position 48 is critical to conformational change of
the inhibitor subsite. Direct contacts from the backbone
oxygen of the mutated residue (O(48)) to the side-chain
amide group (HNP2) of P2, and to the backbone amide
proton (HNbb) of the inhibitor are illustrated by Fig. 8.
The O(48)-HNbb(SQV) distance was, on average, 1.95 A˚
for the wt and extends to 2.25 A˚ in the G48V complex (Fig. 9
A). An increase of the distance is an evidence of decreasing
the hydrogen bond strength.
A loss of the hydrogen bond interactions of residue 48 to
SQV in the mutant complex was conﬁrmed by a very large
distance between O(48) and HNP2(SQV) (Fig. 9 B). The wt
complex shows the close proximity between O(48) and
HNP2(SQV). On the other hand, it is clear that the O(48)-
HNP2 (SQV) distance in the mutant was not in a range of
hydrogen bonding. The rotation of the P2 side chain as
described previously is the cause of the disruption of the
hydrogen bond of O(48)-HNP2 (SQV).
Analysis of these MD results indicates that the mutation at
position 48 decreases the capability of inhibitor binding. A
reduction of the interactions was estimated by calculating the
ab initio energy. The DEG48-SQV decreased ;3.5 kcalmol1
with respect to the DEV48-SQV. The magnitude of changes in
the interaction energy of V48-SQV supports the experimen-
tal Ki data that explain a small decrease (13.5-fold) of
saquinavir sensitivity.
DISCUSSION
The MD simulations were carried out to compare structure
and dynamics of the wt and the G48V HIV-1 PR-saquinavir
complex. In addition, the MD simulations for the four
protonation systems were carried out to obtain structural
models before an evaluation of the ionization form of the
active site residues. The study of protonation state of the
HIV-PR-SQV complex was achieved with extensive energy
calculations using the DFT, ONIOM, and MM/PBSA
methods. Based on our data, both quantum chemical and
molecular dynamics free-energy calculations conﬁrm that
the protonation model of wt-mono25 is the most energeti-
cally favorable case.
The results were in agreement with NMR studies of the
hydroxyethylene isostere inhibitors, pepstatin and KNI-272,
TABLE 3 Mean global RMSD values calculated from a set of
100 snapshot structures of the 600 ps production phase
,RMSD.(A˚)
Dipro Mono25 Mono25# Unpro
wt Backbone 0.90 6 0.13 0.86 6 0.12 0.87 6 0.11 0.83 6 0.11
Heavy atoms 1.56 6 0.22 1.45 6 0.17 1.48 6 0.18 1.39 6 0.15
G48V Backbone 0.83 6 0.11 0.86 6 0.13 0.85 6 0.12 0.86 6 0.12
Heavy atoms 1.39 6 0.18 1.52 6 0.22 1.51 6 0.21 1.47 6 0.19
FIGURE 5 Backbone RMSD between the wild-type and the G48V
structure.
FIGURE 6 HIV-1 PR ﬂap structures of the wt (green) and the G48V
(yellow and blue). Some selected residues and saquinavir are presented in
stick mode. Hydrogen atoms of the enzyme are not shown for simpliﬁcation.
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complexed with the enzyme (Smith et al., 1996; Wang et al.,
1996). In this study, the protonation takes place only on the
D25 side chain. Although the experimental data are not
available for the HIV-1 PR-SQV complex, the structure of
KNI-272 is almost identical to that of saquinavir. They share
the most common features of drug speciﬁcity, including the
capability of binding between the central hydroxylethylene
isostere of the protease inhibitor and the catalytic residues of
the enzyme.
Recently, the protonation state of the HIV-1 PR-SQV
complex was studied using quantum and free-energy
perturbation methods (Lepsik et al., 2004; Nam et al.,
2003). The interaction energy of SQV and the active-site
residues were obtained based on the model taken from the
x-ray structure. The protonation model proposed from those
studies was also monoprotonated D25.
It is worth nothing that the quantum-based method is
a promising tool for the study of receptor-ligand complexes.
The determination of the protonation state of the HIV-PR
active site residues is achievable on the basis of the QM
results. In particular, the ONIOM method has extended the
limitation of system size by the pure QM method. As
demonstrated by the ONIOM results, the enzyme-inhibitor
interactions of the catalytic region and the 5 A˚ surrounding
residues are important for stabilizing the complex. The effect
of the long-distance range on the interaction energy was not
dominant at the MM level. Nevertheless, the method should
be used with some proper care. The effect of the boundary
resulting from incompatibility between molecular orbital
wave functions in the QM part and the MM region may drive
unrealistic energy values (Morokuma, 2002).
An effect of solvent environment, which remains un-
obvious in quantum approach, has been fulﬁlled with the
calculations of binding free energy. The binding free energy
of wt-mono25 obtained fromMM/PBSA was;2 kcal mol1
lower than that of the other states (Table 1). The difference
was contributed from DGsol rather than DE
MM. Not
surprisingly, DEMM of the three protonation model were
almost equivalent (Table 2). Among all three systems, the
only difference, that is the ionizable groups of D25 and D25#,
cannot be well described by the empirical force-ﬁeld energy.
In addition, the inﬂuence of the solvent to the protonation site
was trivial on the basis of the radial distribution function plot
(Wittayanarakul et al., 2005). The radial distribution function
FIGURE 7 Fluctuation of xP1, xP1#, xP2, xP2#, and xP3 corresponding to
the dihedral angles of the inhibitor side chains P1, P1#, P2, P2#, and P3,
respectively.
FIGURE 8 Conformational change of SQV at the P2
side chain. The rotation of the P2 subsite and the
hydrogen bonds are illustrated.
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of the hydroxylethylene oxygen of SQV showed an exclusion
of water molecules from the protonation site. In this case, the
energy information obtained from DFT and ONIOM were
reliable. We anticipate that a method for the correction of the
MM energy term by the QM treatment in MM/PBSA
approach will be valuable for biomolecular research.
The binding pattern at the active site of the wt complex
was similar that of the G48V as shown by the very low
RMSD of residues E21–D30. Importantly, the interaction
energy of the triad residues to SQV was insigniﬁcantly dif-
ferent between the wt and the G48V complexes. The results
indicated the signature residue mutation developed in the pri-
mary resistance does not inﬂuence the interactions at the
active site.
Signiﬁcant changes were located at the protein ﬂaps.
Moreover, the ﬂap structure of chain A was different from
that of chain B. This is caused by different interactions of
the enzyme to the asymmetric inhibitor. Particularly, the
perturbation adopts heavily on the ﬂap conformation of
chain A rather than chain B. The slide of ﬂap A in the G48V
mutant seems to overcome a potential steric conﬂict caused
by the substituted valine. As shown in Fig. 6, position 48 was
in close contact with the F53 side chain of the enzyme and
the P2 and P3 groups of SQV. Since the substituted valine
of the mutant cannot be entirely accommodated in the
hydrophobic pocket due to steric conﬂict of the dimethyl
groups with the F53 and P3 side chains, the ﬂap, therefore,
shifted toward the symmetric axis of the enzyme. This
rearrangement additionally destabilizes hydrogen bonding
between the backbone CO of residue 48 of the enzyme and
the P2 subsite of the inhibitor. In addition to the ﬂap
movement, the side chain of hydrophobic F53 became
solvent-exposed to avoid steric clashes with V48 and Met-
46, whereas an orientation of F53# in ﬂap B of the mutant
was not changed dramatically.
The role of the HIV-1 PR mutation at the ﬂexible ﬂap has
been considerably debated about whether it would facilitate
the binding reaction or reduce stability of the inhibitor, or
both (Ermolieff et al., 1997; Hong et al., 1997; Maschera
et al., 1996). The crystal structure of the double mutant
G48V/L90M complexed with SQV revealed side-chain
rearrangement of the P2 subsite and the F53 of the enzyme
similar to this study (Hong et al., 2000). Particularly, the
missing of hydrogen bonding between the P2 subsite and the
backbone C¼O of residue 48 was also found in the x-ray
structure of the double mutant. The crystal structure of G48H
complexed with peptidic inhibitor U-89360E reported a de-
crease of ﬂap mobility to stabilize the ligand (Hong et al.,
1997).
Apparently the conformational change of the P2 subsite
was an inﬂuence of steric conﬂict of the mutation at position
48. Importantly, it reduced saquinavir susceptibility to the
mutant by interrupting the hydrogen bond interactions. Thus,
a new drug with reduced steric repulsion on P2 could be
designed to enhance the activity toward this mutant strain.
The x-ray structural data provided relevant information,
insight into the molecular mechanism of HIV resistance to
the protease inhibitor. Dynamic details of the full-atomic
representation of the complex were required for further
investigation. Therefore, MD simulation offers a good op-
portunity to fulﬁll basic information that could be useful in
understanding the drug resistance mechanism and helpful in
designing an anti-HIV inhibitor.
CONCLUSIONS
Molecular dynamics simulations of the wt and the G48V
HIV-1 protease complexed with SQV were carried out to
investigate the molecular basis of drug resistance. The MD
FIGURE 9 Distance trajectories of hydrogen bond-
ing involving the CO backbone of residue 48.
FIGURE 10 Schematic representation of the three-layer ONIOM extrap-
olation scheme.
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results combined with quantum chemical calculations extend
the capability of molecular modeling methods to study some
biological systems, of which structural information is limited.
This study showed that both complexes form the monoproto-
nation on D25. Overall tertiary structure of the wt and the
mutant protease was not signiﬁcantly altered. Particularly,
structure and interactions at the central active site remain
unchanged. However, conformational differences between
the wt and the G48V mutant were on the protein ﬂap.
The conformational change of the P2 subsite decreased the
strength of hydrogen bonding of the backbone CO of the
residue 48 to SQV. The change in interaction energies was
comparable to the experimental Ki data. These observations
provide useful information for designing potent HIV-1 PR
inhibitors.
APPENDIX: ONIOM CALCULATIONS
The key interactions centered on SQV and the catalytic residues were treated
at a high level of calculations, whereas the environmental effect of the entire
protein was calculated at a lower level of calculations. In this study, three-
layered ONIOM (ONIOM3) was employed (Morokuma, 2002).
On the basis of the ONIOM3method shown in Fig. 10, the total energy of
the system can be obtained from ﬁve independent calculations as
E
ONIOM3 ¼ E½Low; real1E½Med; intermediate
1E½High; inner  E½Low; intermediate
 E½Med; inner ð11Þ
or
E
ONIOM3 ¼ E61E51E4 E3 E2; (12)
where real denotes the entire system, of which the energy (E6) is calculated
at the low level. For the intermediate layer, the energy is computed at both
the medium (E5) and low (E3) level. For the inner layer, the energy is
obtained at both high (E4) and medium (E2) level.
As shown by Fig. 11, the structure of the HIV-1 PR-SQV complex was
partitioned into three parts represented by inner layer (A), intermediate layer
(A 1 B), and real layer (A 1 B 1 C). The atoms of the enzyme and the
inhibitor deﬁned to each layers were described in the Methods section.
To obtain the interaction energy of the HIV-1 PR/SQV complex (DEcpx),
one can be expressed as
DEcpx ¼ Ecpx  EPR  ESQV; (13)
where Ecpx, EPR, and ESQV are the total energy of the HIV-1 PR/SQV
complex, HIV-1 PR and SQV, respectively.
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